AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26312445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections with ropivacaine (100 mg) and ketorolac (15 mg)
Number of subjects: 80
Study 26312445 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 80
Study 24382594 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment plus cognitive remediation
Number of subjects: 175
Study 24382594 — intervention group
Group type: COMPARATOR
Intervention: Supported employment
Number of subjects: 175
Study 22122202 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 347
Study 22122202 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 347
Study 22122202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 20364555 — intervention group
Group type: EXPERIMENTAL
Intervention: Siriraj Leg Lock (SLL) brace
Number of subjects: 100
Study 20364555 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 17645430 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT with CM
Number of subjects: 136
Study 17645430 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT without CM
Number of subjects: 136
Study 17645430 — intervention group
Group type: EXPERIMENTAL
Intervention: DC with CM
Number of subjects: 136
Study 17645430 — intervention group
Group type: EXPERIMENTAL
Intervention: DC without CM
Number of subjects: 136
Study 16287791 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent condom use (greater than 75% of sexual acts)
Number of subjects: 1843
Study 16287791 — intervention group
Group type: COMPARATOR
Intervention: Less frequent condom use (0% to 25% and 25% to 75% of sexual acts)
Number of subjects: 1843
Study 16287791 — intervention group
Group type: COMPARATOR
Intervention: Condom use
Number of subjects: 1843
Study 12153608 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.7 IU/m2/day
Number of subjects: 58
Study 12153608 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.5 IU/m2/day
Number of subjects: 58
Study 12153608 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.0 IU/m2/day
Number of subjects: 58
Study 12153608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 10209831 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock energy programmed at twice DFT+
Number of subjects: 176
Study 10209831 — intervention group
Group type: COMPARATOR
Intervention: Shock energy at maximum output (34 J)
Number of subjects: 176
Study 10209831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 176
Study 7796255 — intervention group
Group type: EXPERIMENTAL
Intervention: initial family assessment; child and family seen together
Number of subjects: 100
Study 7796255 — intervention group
Group type: COMPARATOR
Intervention: individual assessment; child and parents seen in parallel
Number of subjects: 100
Study 7796255 — intervention group
Group type: EXPERIMENTAL
Intervention: initial family interview
Number of subjects: 100
Study 7796255 — intervention group
Group type: EXPERIMENTAL
Intervention: long term therapy
Number of subjects: 100
Study 2394504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% calories from fat) for 4 menstrual cycles
Number of subjects: 31
Study 2394504 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% calories from fat) for 4 menstrual cycles
Number of subjects: 31
Study 7004635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (doxorubicin every 21 days, cyclophosphamide daily)
Number of subjects: 96
Study 7004635 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rotation schedule (doxorubicin every 42 days, cyclophosphamide for 21 days of the 42-day cycle)
Number of subjects: 96
Study 30021811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cord blood 25OHD at birth (>31 ng/mL)
Number of subjects: 0
Study 30021811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood 25OHD levels >31 ng/mL
Number of subjects: 0
Study 28224946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 0
Study 28224946 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrated group (VG) - mechanical vibration applied on quadriceps muscles, 10 min, three times a day for three consecutive days.
Number of subjects: 350
Study 25850540 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - placebo vibratory stimulation (sham treatment).
Number of subjects: 350
Study 23650295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsolable crying >20 minutes per day
Number of subjects: 587
Study 23650295 — intervention group
Group type: COMPARATOR
Intervention: Colic (defined by Wessel's criteria)
Number of subjects: 587
Study 21899766 — intervention group
Group type: EXPERIMENTAL
Intervention: One-page ADR information letters administered at three occasions during 2008 to all physicians and nurses in the intervention units
Number of subjects: 151
Study 21899766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study 18458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Goosestep training without forcefully striking the ground
Number of subjects: 40
Study 18458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Goosestep training with forcefully striking the ground
Number of subjects: 40
Study 17383520 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based video instruction (CBVI)
Number of subjects: 0
Study 17383520 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent expert feedback
Number of subjects: 0
Study 17383520 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary expert feedback
Number of subjects: 0
Study 17383520 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 0
Study 16799399 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg daily and fenofibrate 160 mg daily (PPAR group)
Number of subjects: 24
Study 16799399 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 5 mg daily and atorvastatin 10 mg daily (non‐PPAR group)
Number of subjects: 24
Study 14709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23
Study 14709198 — intervention group
Group type: COMPARATOR
Intervention: Intensive subcutaneous insulin therapy (ISIT)
Number of subjects: 23
Study 10815784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299
Study 10815784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 8781013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention (physician-delivered brief quit-smoking advice and counseling)
Number of subjects: 659
Study 8781013 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (usual care)
Number of subjects: 659
Study 1531044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg intravenous dose
Number of subjects: 3
Study 1531044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg oral dose
Number of subjects: 3
Study 1531044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 3
Study 6435483 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl injection
Number of subjects: 0
Study 6435483 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular fentanyl injection
Number of subjects: 0
Study 31234962 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthMap trial (online self-management program)
Number of subjects: 728
Study 28056076 — intervention group
Group type: EXPERIMENTAL
Intervention: Laerdal QCPR® (QCPR group)
Number of subjects: 144
Study 28056076 — intervention group
Group type: COMPARATOR
Intervention: Standard instructor-based feedback (SF group)
Number of subjects: 144
Study 26219446 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cognitive behavioral therapy based occupational therapy (OT-CBSM)
Number of subjects: 55
Study 26219446 — intervention group
Group type: COMPARATOR
Intervention: Home program (control group)
Number of subjects: 55
Study 23726746 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 98
Study 23726746 — intervention group
Group type: COMPARATOR
Intervention: Untrained residents (control group)
Number of subjects: 98
Study 22054017 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 436
Study 22054017 — intervention group
Group type: COMPARATOR
Intervention: Usual brief advice (control)
Number of subjects: 436
Study 18434578 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mmol/L Ca rinse
Number of subjects: 13
Study 18434578 — intervention group
Group type: COMPARATOR
Intervention: 12 mmol/L NaF rinse
Number of subjects: 13
Study 18434578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca rinse followed by F rinse
Number of subjects: 13
Study 17398039 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to reduce behaviors associated with HIV and HCV transmission
Number of subjects: 3129
Study 17398039 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 3129
Study 14725783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted multimedia training course for intravenous injection
Number of subjects: 81
Study 14725783 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study 11739054 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff Internist (SI) led intervention
Number of subjects: 44
Study 11739054 — intervention group
Group type: COMPARATOR
Intervention: Resident Instructor (RI) led intervention
Number of subjects: 44
Study 8996137 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PAM alone (10 mg/m2, 15 mg/m2, 17.5 mg/m2, 20 mg/m2)
Number of subjects: 16
Study 8996137 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PAM plus WBH (at various doses)
Number of subjects: 16
Study 8996137 — intervention group
Group type: COMPARATOR
Intervention: WBH alone
Number of subjects: 16
Study 8355124 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 59
Study 8355124 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1290 mg/L calcium
Number of subjects: 59
Study 8355124 — intervention group
Group type: COMPARATOR
Intervention: Standard formula with 545 mg/L calcium
Number of subjects: 59
Study 2446463 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ECT
Number of subjects: 11
Study 2446463 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study 31397179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily
Number of subjects: 239
Study 31397179 — intervention group
Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP) gel 90 mg daily
Number of subjects: 239
Study 29100197 — intervention group
Group type: EXPERIMENTAL
Intervention: Family video message
Number of subjects: 126
Study 29100197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature video
Number of subjects: 126
Study 29100197 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 27858072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex and minocycline hydrochloride
Number of subjects: 120
Study 27858072 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional root canal therapy)
Number of subjects: 120
Study 27858072 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Vitapex and minocycline hydrochloride)
Number of subjects: 120
Study 26553836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily
Number of subjects: 46
Study 26553836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23672570 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of bronchoconstriction measured as slope of FEV(1) and Borg score
Number of subjects: 112
Study 23672570 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg score at a 20% decrease in FEV(1) (PS(20))
Number of subjects: 112
Study 23672570 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatability of Borg scores
Number of subjects: 112
Study 20496730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Xuanzhong (GB 39) combined with Chinese herbs pyrogenic dressing therapy
Number of subjects: 66
Study 20496730 — intervention group
Group type: COMPARATOR
Intervention: Common acupuncture (Yanglingquan (GB 34), Kunlun (BL 60), etc.)
Number of subjects: 66
Study 20496730 — intervention group
Group type: COMPARATOR
Intervention: Common acupuncture
Number of subjects: 66
Study 19117256 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality female condom
Number of subjects: 233
Study 19117256 — intervention group
Group type: COMPARATOR
Intervention: Prototype female condom (FC2)
Number of subjects: 233
Study 16753251 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypersons responding to a medical emergency (CPR/AED training)
Number of subjects: 1243
Study 16753251 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypersons responding in residential settings
Number of subjects: 1243
Study 16753251 — intervention group
Group type: EXPERIMENTAL
Intervention: Females and non-native English speakers among lay responders
Number of subjects: 1243
Study 16753251 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative responses from lay responders
Number of subjects: 1243
Study 14629771 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 39
Study 14629771 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided needle aspiration with metronidazole
Number of subjects: 39
Study 10735900 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after each chemotherapy course
Number of subjects: 67
Study 10735900 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after R3 courses
Number of subjects: 67
Study 10735900 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after chemotherapy
Number of subjects: 67
Study 10735900 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF (lenogastrim) vs non-G‐CSF group
Number of subjects: 67
Study 8823852 — intervention group
Group type: EXPERIMENTAL
Intervention: SmithKline Beecham vaccine (Engerix‐B, 10 micrograms/dose)
Number of subjects: 428
Study 8823852 — intervention group
Group type: COMPARATOR
Intervention: Merck vaccine (Recombivax HB, 2.5 micrograms/dose)
Number of subjects: 428
Study 8823852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 428
Study 1603470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioscint
Number of subjects: 10
Study 1603470 — intervention group
Group type: COMPARATOR
Intervention: Gamma camera
Number of subjects: 10
Study 3881648 — intervention group
Group type: EXPERIMENTAL
Intervention: Overeating (+1000 kcal/m2 above isocaloric requirements)
Number of subjects: 6
Study 3881648 — intervention group
Group type: EXPERIMENTAL
Intervention: Undereating (400 kcal/d)
Number of subjects: 6
Study 30825395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency intervention (biweekly SMS for 6 months)
Number of subjects: 1362
Study 30825395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency intervention (monthly SMS for 6 months)
Number of subjects: 1362
Study 30825395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS)
Number of subjects: 1362
Study 30423575 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV) with smoking-related cues
Number of subjects: 20
Study 30423575 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV) with neutral cues
Number of subjects: 20
Study 30423575 — intervention group
Group type: COMPARATOR
Intervention: Placebo with smoking-related cues
Number of subjects: 20
Study 30423575 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV)
Number of subjects: 20
Study 27393604 — intervention group
Group type: EXPERIMENTAL
Intervention: BEATVIC training (body-oriented resilience training with elements of kickboxing)
Number of subjects: 0
Study 27393604 — intervention group
Group type: COMPARATOR
Intervention: Social activation (control condition)
Number of subjects: 0
Study 24359298 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages designed to discourage smokers from trying snus
Number of subjects: 1836
Study 24359298 — intervention group
Group type: EXPERIMENTAL
Intervention: High efficacy messages
Number of subjects: 1836
Study 24359298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low efficacy messages
Number of subjects: 1836
Study 24359298 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smokeless ads
Number of subjects: 1836
Study 22768640 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased boot weight
Number of subjects: 27
Study 22768640 — intervention group
Group type: EXPERIMENTAL
Intervention: More flexible soles
Number of subjects: 27
Study 22768640 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot weight
Number of subjects: 27
Study 19793149 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic navigation (RN) guided approach
Number of subjects: 60
Study 19793149 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation approach
Number of subjects: 60
Study 18447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of untreated psychosis (DUP)
Number of subjects: 423
Study 18447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-morbid social adaptation
Number of subjects: 423
Study 18447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-morbid school adaptation
Number of subjects: 423
Study 15808251 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine purite
Number of subjects: 31
Study 15808251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 31
Study 12516106 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using 3% ALA in Intrasite Gel applied topically for 3 hours.
Number of subjects: 25
Study 12516106 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 25
Study 11739975 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery (MCA) territory
Number of subjects: 23
Study 11739975 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilar artery (BA) territory
Number of subjects: 23
Study 11739975 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study 9194010 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 0
Study 9194010 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 0
Study 1375059 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine deficiency disorders (IDD)
Number of subjects: 0
Study 1375059 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium deficiency
Number of subjects: 0
Study 1375059 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocyanate overload from poorly detoxified cassava
Number of subjects: 0
Study 2862514 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical injection of vasopressin
Number of subjects: 0
Study 2862514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29608680 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (4 hours) of piperacillin-tazobactam or ceftazidime
Number of subjects: 105
Study 29608680 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime
Number of subjects: 105
Study 29608680 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (4 hours) of beta-lactams
Number of subjects: 105
Study 29608680 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion (30 minutes) of beta-lactams
Number of subjects: 105
Study 26351780 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3023703 (30 mg)
Number of subjects: 48
Study 26351780 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (400 mg)
Number of subjects: 48
Study 26351780 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3023703 (15 mg)
Number of subjects: 48
Study 25038356 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional home initiation of HIV care (including 2 weeks of ART if eligible)
Number of subjects: 16660
Study 25038356 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 16660
Study 25038356 — intervention group
Group type: EXPERIMENTAL
Intervention: Home initiation of HIV care
Number of subjects: 16660
Study 22402733 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modification (EM) program
Number of subjects: 2060
Study 22402733 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 2060
Study 20129825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/ml GM‐CSF
Number of subjects: 73
Study 20129825 — intervention group
Group type: COMPARATOR
Intervention: Control (without GM‐CSF)
Number of subjects: 73
Study 18690630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealer (BVS)
Number of subjects: 61
Study 18690630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically coagulating shears (UCS)
Number of subjects: 61
Study 18690630 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrosurgery scissors (MES)
Number of subjects: 61
Study 15979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for knee OA, 2h daily, 5 days per week for 6 weeks
Number of subjects: 83
Study 15979009 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 83
Study 15979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for patients <65 years
Number of subjects: 83
Study 12917242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 1 g meropenem
Number of subjects: 12
Study 12917242 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h infusion of 1 g meropenem
Number of subjects: 12
Study 12917242 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h infusion of 0.5 g meropenem
Number of subjects: 12
Study 12352219 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 21